Please cite this article in press Shweta Manoj Dhule et al., Targeting Hemostasis Dysfunction And Inflammation In Covid-19 Patients: Potential Therapeutics Avenues Through Viral And Host Molecules , Indo Am. J. P. Sci, 2024; 11 (02).

1. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020; 579(7798): 265-9.[ http://dx.doi.org/10.1038/s41586-020-2008-3]] [PMID: 32015508]
2. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020; 181(2): 281-292.e [http://dx.doi.org/10.1016/j.cell.2020.02.058] [PMID: 32155444]
3. Aronson KJ, Ferner RE, DeVito N, Heneghan C. COVID-19 trials registered up to 8 March 2020: An analysis of 382 studies. The Centre for Evidence-Based Medicine 20. [ https://www.cebm.net/COVID-19/registered-trials-and-analysis/]
4. Launch of a European clinical trial against COVID-19 INSERM (PRESS ROOM) 2020 [https://presse.inserm.fr/lancement-dun-essai-clinique-europeen-contre-le-COVID-19/38737/]
5. Who.int. 2021. “Solidarity” clinical trial for COVID-19 treatments. [online] Available at: https://www.who.int/blueprint/priority-diseases/keyaction/Table_of_therapeutics_Appendix_17022020.pdf?ua=1
6. Xie J, Covassin N, Fan Z, et al. Association between hypoxemia and mortality in patients with COVID-19. Mayo Clin Proc 2020; 95(6):1138-47.[http://dx.doi.org/10.1016/j.mayocp.2020.04.006] [PMID: 32376101]
7. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020; 18(6): 1421-4.[http://dx.doi.org/10.1111/jth.14830] [PMID: 32271988]
8. Zuo T, Zhang F, Lui GCY,et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization [published online ahead of print, 2020 May 20]. Gastroenterology 2020; S0016-5085(20): 34701-6.
9. Gu S, Chen Y, Wu Z,et al. Alterations of the gut microbiota in patients with COVID-19 or H1N1 influenza. Clin Infect Dis 2020[http://dx.doi.org/10.1093/cid/ciaa709]
10. Chan JF, Yuan S, Kok KH,et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet 2020;395(10223): 514-23.[http://dx.doi.org/10.1016/S0140-6736(20)30154-9] [PMID:31986261]
11. Mogensen TH, Paludan SR. Molecular pathways in virus-induced cytokine production. Microbiol Mol Biol Rev 2001; 65(1): 131-50.[http://dx.doi.org/10.1128/MMBR.65.1.131-150.2001] [PMID:11238989]
12. Jose RJ, Manuel A. COVID-19 cytokine storm: The interplay between inflammation and coagulation. Lancet Respir Med 2020; 8(6): e46-7.
[http://dx.doi.org/10.1016/S2213-2600(20)30216-2] [PMID:32353251]
13. Serhan CN. Novel lipid mediators and resolution mechanisms in acute inflammation: To resolve or not? Am J Pathol 2010; 177(4): 1576-91.[http://dx.doi.org/10.2353/ajpath.2010.100322 [PMID: 20813960]
14. Schwarz KB. Oxidative stress during viral infection: A review. Free Radic Biol Med 1996; 21(5): 641-9. [http://dx.doi.org/10.1016/0891-5849(96)00131-1 ][PMID: 8891667]
15. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A Meta-analysis. JAMA 324(13): 1330-41. [http://dx.doi.org/10.1001/jama.2020.17023]
16. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020;130(5): 2620-9. [http://dx.doi.org/10.1172/JCI137244 ] [PMID: 32217835]
17. Zhou F, Yu T, Du R,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054-62 [http://dx.doi.org/10.1016/j.jcv.2020.104362]
18. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus Infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol 2020;
127: 104362.
[http://dx.doi.org/10.1016/j.jcv.2020.104362] [PMID: 32305883]
19. Yu HH, Qin C, Chen M, Wang W, Tian DS. D-dimer level is Associated with the severity of COVID-19. Thromb Res 2020; 195:219-25.
[http://dx.doi.org/10.1016/j.thromres.2020.07.047] [PMID: 32777639]
20. Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 Patients. Ann Hematol 2020; 99(6): 1205-8.
[http://dx.doi.org/10.1007/s00277-020-04019-0] [PMID: 32296910]
21. Ji HL, Zhao R, Matalon S, Matthay MA. Elevated plasmin(ogen) as a Common risk factor for COVID-19 susceptibility. Physiol Rev 2020;100(3): 1065-75.
[http://dx.doi.org/10.1152/physrev.00013.2020] [PMID: 32216698]
22. Bautista-Vargas M, Bonilla-Abadía F, Cañas CA. Potential role for tissue factor in the pathogenesis of hypercoagulability associated with in COVID-19. J Thromb Thrombolysis 2020; 50(3): 479-83.
[published online ahead of print, 2020 Jun 9]
[http://dx.doi.org/10.1007/s11239-020-02172-x] [PMID: 32519164]
23. Van der Poll T. Tissue factor as an initiator of coagulation and Inflammation in the lung. Crit Care 2008; 126: S3.
[http://dx.doi.org/10.1186/cc7026]
24. Ferraz CR, Arrahman A, Xie C, et al. Multifunctional toxins in snake Venoms and therapeutic implications: From pain to hemorrhage and Necrosis Frontiers in Ecology and Evolution 2019; 7www.frontIersin.org
25. Ye S, Xia H, Dong C, et al. Identification and characterization of Iflavirus 3C-like protease processing activities. Virology 2012; 428(2):136-45.
[http://dx.doi.org/10.1016/j.virol.2012.04.002] [PMID: 22534091]
26. Chen S, Chen LL, Luo HB, et al. Enzymatic activity characterization Of SARS coronavirus 3C-like protease by fluorescence resonance Energy transfer technique. Acta Pharmacol Sin 2005; 26(1): 99-106.
[http://dx.doi.org/10.1111/j.1745-7254.2005.00010.x] [PMID: 15659121]
27. Xia B, Kang X. Activation and maturation of SARS-CoV main Protease. Protein Cell 2011; 2(4): 282-90.
[http://dx.doi.org/10.1007/s13238-011-1034-1] [PMID: 21533772]
28. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181(2): 271-280.e8.
[http://dx.doi.org/10.1016/j.cell.2020.02.052] [PMID: 32142651]
29. Dahms SO, Arciniega M, Steinmetzer T, Huber R, Then ME. Structure of the unliganded form of the proprotein convertase furin suggests Activation by a substrate-induced mechanism. Proc Natl Acad Sci USA2016; 113(40): 11196- 201.[http://dx.doi.org/10.1073/pnas.1613630113 ] [PMID: 27647913]
30. Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains A furin-like cleavage site absent in CoV of the same clade. Antiviral Res 2020; 176: 104742 [http://dx.doi.org/10.1016/j.antiviral.2020.104742] [PMID: 32057769]
31. Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci USA 2020; 117(21): 11727-34.[http://dx.doi.org/10.1073/pnas.2003138117] [PMID: 32376634]
32. Patick AK, Potts KE. Protease inhibitors as antiviral agents. Clin Microbiol Rev 1998; 11(4): 614-27.
[http://dx.doi.org/10.1128/CMR.11.4.614] [PMID: 9767059]
33. Chen YW, Bennu Yiu CP, Wong KY. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL) structure: Virtual screening Reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Research 2020; 9: 129.
34. Jordheim LP, Durantel D, Zoulim F, Dumontet C. Advances in the Development of nucleoside and nucleotide analogues for cancer and Viral diseases. Nat Rev Drug Discover 2013; 12: 447-64. [http://dx.doi.org/10.1038/nrd4010]
35. El-Fakharany EM, Sánchez L, Al-Mehdar HA, Redwan EM. Effectiveness of human, camel, bovine and sheep lactoferrin on the Hepatitis C virus cellular infectivity: Comparison study. Virol J 2013; 10: 199.
[http://dx.doi.org/10.1186/1743-422X-10-199] [PMID: 23782993]
36. Zwirzitz A, Reiter M, Skrabana R, et al. Lactoferrin is a natural Inhibitor of plasminogen activation. J Biol Chem 2018; 293(22): 8600-13. [http://dx.doi.org/10.1074/jbc.RA118.003145] [PMID: 29669808]
37. Hendrixson DR, Qiu J, Shewry SC, et al. Human milk lactoferrin is a Serine protease that cleaves Haemophilus surface proteins at arginine rich sites. Mol Microbiol 2003; 47(3): 607-17. [http://dx.doi.org/10.1046/j.1365-2958.2003.03327.x] [PMID: 12535064]
38. Giansanti F, Panella G, Leboffe L, Antonini G. Lactoferrin from milk: Nutraceutical and pharmacological properties. Pharmaceuticals (Basel) 2016; 9(4): 61.[http://dx.doi.org/10.3390/ph9040061] [PMID: 27690059]
39. Campione E, Lanna C, Cosio T, et al. Pleiotropic effect of Lactoferrin In the prevention and treatment of COVID-19 infection randomized Clinical trial, in vitro and in silico preliminary evidence https://www.biorxiv.org/content/10.1101/2020.08.11.244996v3
40. Tandon D, Haque MM, Gote M, et al. A prospective randomized, Double-blind, placebo-controlled, dose-response relationship study to Investigate efficacy of fructo-oligosaccharides (FOS) on human gut Microflora. Sci Rep 2019; 9(1): 5473. [http://dx.doi.org/10.1038/s41598-019-41837-3] [PMID: 30940833]
41. Morozov V, Hansman G, Hanisch FG, Schroten H, Kunz C. Human Milk oligosaccharides as promising antivirals. Mol Nutr Food Res 2018; 62(6): e1700679. [http://dx.doi.org/10.1002/mnfr.201700679] [PMID: 29336526]
42. Yang B, Chuang H, Chen RF. Protection from viral infections by human milk oligosaccharides: Direct blockade and indirect modulation of intestinal ecology and immune reactions. Open Glycosci 2012; 5:19-25.[http://dx.doi.org/10.2174/1875398101205010019]
43. Etzold S, Bode L. Glycan-dependent viral infection in infants and the role of human milk oligosaccharides. Curr Opin Virol 2014; 7: 101-7.[http://dx.doi.org/10.1016/j.coviro.2014.06.005] [PMID: 25047751]
44. Morrow AL, Ruiz-Palacios GM, Jiang X, Newburg DS. Human-milk glycans that inhibit pathogen binding protect breast-feeding infants against infectious diarrhea. J Nutr 2005; 135(5): 1304-7.[http://dx.doi.org/10.1093/jn/135.5.1304] [PMID: 15867329]
45. Singh R, Mal G, Kumar D, Patil NV, Pathak KML. Camel milk: An important natural adjuvant. Agric Res 2017; 6(4): 327-40.[http://dx.doi.org/10.1007/s40003-017-0284-4]
46. Al haj OA and Al Kanhal HA. Compositional, technological and nutritional aspects of dromedary camel milk. Int Dairy J 2010; 20:811e-21.
47. Abrhaley A, Leta S. Medicinal value of camel milk and meat. J Appl Anim Res 2018; 46: 552-8.[ http://dx.doi.org/10.1080/09712119.2017.1357562]
48. El-Fakharany EM, El-Baky NA, Linjawi MH, et al. Influence of camel milk on the hepatitis C virus burden of infected patients. Exp Ther Med 2017; 13(4): 1313-20. [http://dx.doi.org/10.3892/etm.2017.4159] [PMID: 28413471]
49. el Agamy EI, Ruppanner R, Ismail A, Champagne CP, Assaf R.Antibacterial and antiviral activity of camel milk protective proteins. J Dairy Res 1992; 59(2): 169-75. [http://dx.doi.org/10.1017/S0022029900030417] [PMID: 1319434]
50. Giansanti F, Panella G, Leboffe L, Antonini G. Lactoferrin from milk:Nutraceutical and pharmacological properties. Pharmaceuticals (Basel)2016; 9(4): E61. [http://dx.doi.org/10.3390/ph9040061] [PMID: 27690059]
51. 55. Ramani S, Stewart CJ, Laucirica DR, et al. Human milk oligosaccharides, milk microbiome and infant gut microbiome modulate neonatal rotavirus infection. Nat Commun 2018; 9(1): 5010. [http://dx.doi.org/10.1038/s41467-018-07476-4] [PMID: 30479342]
52. Weichert S, Koromyslova A, Singh BK, et al. Structural basis for norovirus inhibition by human milk oligosaccharides. J Virol 2016; 90(9): 4843-8. [http://dx.doi.org/10.1128/JVI.03223-15] [PMID: 26889023]
53. Errasfa M. Milk oligosaccharides and lectins as candidates for clinical trials against COVID-19. Curr Nutr Food Sci 2020; 16: 1. [http://dx.doi.org/10.2174/1573401316999200819125355]
54. Carter A. Mitchell, Koreen Ramessar, and Barry R. O’Keefe. Antiviral lectins: Selective inhibitors of viral entry. Antiviral Res 2017; 142: 37-54. [http://dx.doi.org/10.1016/j.antiviral.2017.03.007]
55. Keyaerts E, Vijgen L, Pannecouque C, et al. Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle. Antiviral Res 2007; 75(3): 179-87. [http://dx.doi.org/10.1016/j.antiviral.2007.03.003] [PMID: 17428553]
56. Kumaki Y, Wandersee MK, Smith AJ, et al. Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB/c mouse model by stinging nettle lectin, Urtica dioica agglutinin. Antiviral Res 2011; 90(1): 22-32. [http://dx.doi.org/10.1016/j.antiviral.2011.02.003] [PMID: 21338626]
57. Liu YM, Shahed-Al-Mahmud M, Chen X, et al. A carbohydratebinding protein from the edible lablab beans effectively blocks the infections of influenza viruses and SARS-CoV-2. Cell Rep 2020; 32(6): 108016. [http://dx.doi.org/10.1016/j.celrep.2020.108016] [PMID: 32755598]
58. Gordts SC, Renders M, Férir G, et al. NICTABA and UDA, two GlcNAc-binding lectins with unique antiviral activity profiles. J Antimicrob Chemother 2015; 70(6): 1674-85. [http://dx.doi.org/10.1093/jac/dkv034] [PMID: 25700718]
59. van der Meer FJ, de Haan CA, Schuurman NM, et al. Antiviral activity of carbohydrate-binding agents against Nidovirales in cell culture. Antiviral Res 2007; 76(1): 21-9. [http://dx.doi.org/10.1016/j.antiviral.2007.04.003] [PMID: 17560666]
60. Darakhshan S, Bidmeshki Pour A, Hosseinzadeh Colagar A, Sisakhtnezhad S. Thymoquinone and its therapeutic potentials. Pharmacol Res 2015; 95-96: 138-58. [http://dx.doi.org/10.1016/j.phrs.2015.03.011] [PMID: 25829334]
61. Goyal SN, Prajapati CP, Gore PR, et al. Therapeutic potential and pharmaceutical development of thymoquinone: A multitargeted molecule of natural origin. Front Pharmacol 2017; 8: 656[http://dx.doi.org/10.3389/fphar.2017.00656] [PMID: 28983249]
62. Ahmad A, Rehman MU, Ahmad P, Alkharfy KM. COVID-19 and thymoquinone: Connecting the dots. Phytother Res 2020; 34(11): 2786-9. [http://dx.doi.org/10.1002/ptr.6793] [PMID: 32588453]
63. Mohammadabadi MR, Mozafari MR. Enhanced efficacy and bioavailability of thymoquinone using nanoliposomal dosage form. J Drug Deliv Sci Technol 2018; 47: 445-53[http://dx.doi.org/10.1016/j.jddst.2018.08.019]
64. Mohammadabadi MR, Mozafari MR. Development of nanoliposomeencapsulated thymoquinone:Evaluation of loading efficiency and particle characterization. J Biopharm 2019; 11: 39-46.
65. Wolf FI, Cittadini A. Chemistry and biochemistry of magnesium. Mol Aspects Med 2003; 24(1-3): 3-9[http://dx.doi.org/10.1016/S0098-2997(02)00087-0] [PMID: 12537985]
66. Tang CF, Ding H, Jiao RQ, Wu XX, Kong LD. Possibility of magnesium supplementation for supportive treatment in patients with COVID-19. Eur J Pharmacol 2020; 886: 173546. [http://dx.doi.org/10.1016/j.ejphar.2020.173546] [PMID: 32931782]
67. Wallace TC. Combating COVID-19 and building immune resilience: A potential role for magnesium nutrition? J Am Coll Nutr 2020; 39(8): 685-93. [http://dx.doi.org/10.1080/07315724.2020.1785971] [PMID: 32649272]
68. Iotti S, Wolf F, Mazur A, Maier JA. The COVID-19 pandemic: Is there a role for magnesium? Hypotheses and perspectives. Magnes Res 2020; 33(2): 21-7. [http://dx.doi.org/10.1684/mrh.2020.0465] [PMID: 32554340]
69. Tobaiqy M, Qashqary M, Al-Dahery S, et al. Therapeutic management of patients with COVID-19: A systematic review. Infect Preventi in Pract 2020; 2(3): 100061. [http://dx.doi.org/10.1016/j.infpip.2020.100061]
70. Quiros Roldan E, Biasiotto G, Magro P, Zanella I. The possible mechanisms of action of 4-aminoquinolines (chloroquine/ hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis? Pharmacol Res 2020; 158: 104904[http://dx.doi.org/10.1016/j.phrs.2020.104904] [PMID: 32430286]
71. Foscolou A, Critselis E, Panagiotakos D. Olive oil consumption and human health: A narrative review. Maturitas 2018; 118: 60-6[http://dx.doi.org/10.1016/j.maturitas.2018.10.013] [PMID: 30415757]
72. Essouiri J, Abourazzak FE, Lazrak F, et al. Efficacy of argane oil on metabolic syndrome in a moroccan knee osteoarthritis population. Curr Rheumatol Rev 2018; 14(1): 84-8. [http://dx.doi.org/10.2174/1573397112666161205103009] [PMID: 27917705]
73. Eljaoudi R, Elkabbaj D, Bahadi A, Ibrahimi A, Benyahia M, Errasfa M. Consumption of argan oil improves antioxidant and lipid status in hemodialysis patients. Phytother Res 2015; 29(10): 1595-9. [http://dx.doi.org/10.1002/ptr.5405] [PMID: 26101142]